SCHEDULE 13G/A: Biotechnology Value Fund Boosts Zymeworks Stake to 5.2%

Biotechnology Value Fund and its affiliates have increased their aggregate beneficial ownership in Zymeworks Inc. to 5.2% of outstanding common stock as of September 30, 2025.

Summary

• Biotechnology Value Fund, L.P. (BVF) and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P. (BVF2), BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in Zymeworks Inc.
• As of September 30, 2025, the aggregate beneficial ownership by Partners, BVF Inc., and Mark N. Lampert is 3,938,641 shares, representing approximately 5.2% of Zymeworks Inc.'s outstanding common stock.
• This percentage is based on 75,166,196 shares outstanding as of August 5, 2025, as reported in Zymeworks' Quarterly Report on Form 10-Q.
• Individual beneficial ownership stakes include BVF with 2,045,162 shares (2.7%), BVF2 with 1,601,489 shares (2.1%), and Biotechnology Value Trading Fund OS LP with 212,898 shares (0.3%).
• BVF GP Holdings LLC, as the sole member of BVF GP and BVF2 GP, is deemed to beneficially own 3,646,651 shares, representing approximately 4.9% of the outstanding shares.
• All reported shares are held with shared voting and dispositive power among the respective reporting persons.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a substantial beneficial ownership stake by a prominent biotechnology-focused investment fund, suggesting a positive long-term view on Zymeworks Inc. by a sophisticated investor.

Positives

• A significant increase in ownership by a specialized biotechnology investment fund like Biotechnology Value Fund suggests confidence in Zymeworks Inc.'s long-term prospects.
• The aggregate 5.2% stake by a prominent institutional investor could attract further institutional interest and potentially stabilize the stock price.

Industry Context

In the biotechnology sector, significant institutional ownership by specialized funds like Biotechnology Value Fund can signal strong investor conviction in a company's pipeline, technology, or market potential. Such filings are closely watched as they can influence market perception and attract other investors, particularly in a capital-intensive industry like biotech where investor confidence is crucial.

Stakeholder Impact

• Shareholders: The increased institutional ownership by a specialized fund may be viewed positively, potentially increasing investor confidence and attracting further investment, which could support the stock price.
• Management: A significant institutional stake could lead to increased scrutiny or engagement from the investor, potentially influencing strategic decisions, especially given the certification regarding Rule 14a-11 nominations.

Key Dates

Recommendation

The filing indicates a significant institutional stake by a specialized biotechnology fund, which is generally a positive signal of investor confidence. However, a Schedule 13G filing primarily discloses ownership and does not provide new operational or financial performance data. Without additional information on Zymeworks' recent performance, pipeline progress, or strategic developments, a "hold" recommendation is prudent, acknowledging the positive signal from the institutional investment while awaiting more comprehensive company updates. The certification regarding Rule 14a-11 nominations suggests potential for future shareholder engagement, which could be a catalyst.

Keywords

Zymeworks Inc., ZYME, Biotechnology Value Fund, BVF, institutional ownership, Schedule 13G, beneficial ownership, common stock, biotech, investment fund